Variational AI Announces Oversubscribed $5.5 Million Financing to Launch Foundation Model for Small Molecule Drug Discovery
New funding to fuel market expansion of compute efficient foundation model for biopharmaceutical companies
How to drug a novel target in 500 molecules
Research conducted by the Variational AI team: Marshall Drew-Brook, Peter Guzzo, Ahmad Issa, Mehran Khodabandeh, Sara Omar, Jason Rolfe, and Ali Saberali. Searching through the space of synthesizable molecules to find an effective drug candidate is one of the most time-consuming and expensive steps of drug discovery. Once a protein mediating disease has been identified and some […]
Variational AI Selected by ImmVue Therapeutics to Power Immuno-Oncology Drug Discovery
Immuno-Oncology pioneer ImmVue Therapeutics to adopt Enki™Lead Generator to discover first-in-class cancer drugs.
Variational AI and Rakovina announce Collaboration
Rakovina announces potential multi-target engagement with Variational AI focused on DNA Damage Repair (DDR)
Why is QSAR so far behind other forms of machine learning, and what can be done to close the gap?
QSAR models struggle with extrapolation compared to conventional ML tasks like image recognition. Machine learning generalizes effectively when structured to align with its problem domain, suggesting that improving QSAR models may close this gap in drug discovery.
100 AI-generated molecules are worth a 1,000,000 molecule high-throughput screen
Generative AI in drug discovery is showing promise by optimizing molecule searches beyond traditional methods. Variational AI’s Enki algorithm created 100 AI-generated molecules that outperform 1,000,000 in conventional high-throughput screening, highlighting AI’s efficiency in exploring chemical space.
Applicability domains are common in QSAR but irrelevant for conventional ML tasks
Traditional QSAR models are limited to interpolation within known chemical spaces, restricting drug discovery. In contrast, modern machine learning excels at extrapolation, opening new possibilities for exploring untapped chemical compounds and enhancing hit discovery.
Variational AI announces generative AI project with Merck
Variational AI, developer of the Enki™ generative artificial intelligence (AI) platform for drug discovery, today announced a project with Merck Research Labs supported by the CQDM Quantum Leap program.
Variational AI Files Two US Provisional Patents for Potential COVID-19 Drug Created by Generative AI
Variational AI, developer of the Enki™ generative artificial intelligence (AI) drug discovery platform to redefine the economics of drug development, today announced that the company has filed two provisional patents with the United States Patent and Trademark Office
Variational AI Adds Jennifer Hamilton as Advisor
Variational AI, developer of generative AI-based drug discovery platform for novel kinase inhibitors, today announced that it has added industry and scientific leader Jennifer Hamilton, Ph.D. as a company advisor.
